
Foresight Diagnostics: World's most sensitive liquid biopsy provider, detecting early cancer relapse.
foresight-dx.comCrawled Oct 15, 2026
The company provides presentations and publications about precision genomics.
Brittin Davis is Foresight Diagnostics' senior vice president of business and laboratory operations and strategy. At Invitae, she held roles in US laboratory operations, oncology diagnostic strategy, quality control, manufacturing, engineering and operations.
David Kurtz is Foresight Diagnostics' chief medical officer, head of research and cofounder. His research develops methods to detect, monitor and treat hematologic malignancies, drawing on molecular biology, cancer genomics and bioengineering.
Dr. Jake Chabon co-founded Foresight Diagnostics in 2020 and serves as its chief executive officer and chief scientific officer. A molecular biologist and bioinformatic scientist, he has more than 50 peer-reviewed publications and over 7,000 citations.
John Truesdell is Foresight Diagnostics' chief business officer with experience in healthcare sales, marketing, life-cycle management and business development. He previously held business leadership roles at SeQure Dx and Foundation Medicine.
The company says its team is committed to innovating ctDNA tests and MRD detection for cancer diagnostics.
The company offers diagnostic solutions, including the Foresight CLARITY MRD platform.
The company develops diagnostics to support decision-making in oncology drug development and patient care.
Foresight Diagnostics, Inc.'s privacy policy was last updated October 30, 2024.
Foresight Diagnostics and Roche enter a licensing agreement covering Foresight’s PhasED-Seq technology for use in non-Hodgkin lymphoma.
Jun 2024 · NewsNews article
Foresight Diagnostics expands its Series B financing to $73.75 million to advance the Foresight CLARITY MRD platform.
Jun 2024 · NewsNews article
Foresight Diagnostics was featured in a News report covering company developments and industry activity.
Jun 2024 · NewsNews article
Foresight Diagnostics plans to present clinical performance data on its Foresight CLARITY MRD at the IASLC 2025 World Conference on Lung Cancer.
Jun 2024 · PR NewswireNews article